Skip to main content

Pfizer’s $43 billion bid for Seagen aims to broaden company’s cancer portfolio

Pfizer plans to pay $229 per share in cash for Seagen, whose stock soared more than 15% in trading on Monday afternoon. Pfizer’s shares gained about 1.7%.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.